Cyclooxygenase 2 inhibition in patients with non-small cell lung cancer: Is this still a valid target for therapy?

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

(2015) Karen L. Reckamp et al.   CANCER

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer

(2015) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection

(2015) Jonathan H Chen et al.   NATURE MEDICINE

Abstract CT238: Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)

(2015) Martin J. Edelman et al.   CANCER RESEARCH

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

(2014) Barbara J. Gitlitz et al.   Journal of Thoracic Oncology

Prevention and Treatment of Cancer With Aspirin: Where Do We Stand?

(2014) Boris Pasche et al.   SEMINARS IN ONCOLOGY

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

(2013)   LANCET

Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer

(2010) Shirish M. Gadgeel et al.   Journal of Thoracic Oncology

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

(2008) M. J. Fidler et al.   CLINICAL CANCER RESEARCH

Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203

(2008) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY